









Markets
/
Stocks
/
nasdaq-btai
/

BioXcel Therapeutics Inc

BTAI

2.990USD

-0.020-0.66%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

19.79MMarket Cap

LossP/E TTM



BioXcel Therapeutics Inc

2.990

-0.020-0.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

112 / 175

Overall Ranking

405 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

18.500

Target Price

+514.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 504.27% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.27M.

Overvalued

The company’s latest PE is -0.01, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.20M shares, decreasing 14.06% quarter-over-quarter.

Held by Howard Marks

Star Investor Howard Marks holds 284.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.27.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.66, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 120.00K, representing a year-over-year decrease of 89.13%, while its net profit experienced a year-over-year decrease of 131.20%.

Score

Industry at a Glance

Previous score

5.66

Change



Financials

6.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.17

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.01, which is 866.27% below the recent high of -0.08 and -121761.45% above the recent low of -10.11.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for BioXcel Therapeutics Inc is 11.00, with a high of 66.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

18.500

Target Price

+514.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

BioXcel Therapeutics Inc

BTAI

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.44, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 4.79 and the support level at 2.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.44

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.307

Sell

RSI(14)

41.122

Neutral

STOCH(KDJ)(9,3,3)

10.071

Oversold

ATR(14)

0.359

Low Volatility

CCI(14)

-85.857

Neutral

Williams %R

90.909

Oversold

TRIX(12,20)

-1.128

Sell

StochRSI(14)

55.294

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.012

Sell

MA10

3.289

Sell

MA20

3.758

Sell

MA50

3.389

Sell

MA100

2.521

Buy

MA200

3.206

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bioxcel Corp

480.34K

-10.08%

Armistice Capital LLC

288.13K

-7.75%

Murchinson Ltd.

136.08K

UBS Financial Services, Inc.

101.78K

+27.53%

Geode Capital Management, L.L.C.

22.06K

+13.15%

Mack (David J)

16.93K

+11.11%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.